Press Releases

November 1, 2017

Bladder Health Month – Spotlight on IC

May 21, 2014

Aquinox Pharmaceuticals to Present at Upcoming Investor Conferences

May 14, 2014

Aquinox Pharmaceuticals Announces Presentation on FLAGSHIP Study at the 2014 American Thoracic Society International Conference

May 13, 2014

Aquinox Pharmaceuticals Announces First Quarter 2014 Financial Results

March 12, 2014

Aquinox Pharmaceuticals Announces Closing of Initial Public Offering

March 7, 2014

Aquinox Pharmaceuticals Prices Initial Public Offering

December 17, 2013

Aquinox Pharmaceuticals commences Phase 2 clinical trial of AQX-1125 in Chronic Obstructive Pulmonary Disease

July 23, 2013

Aquinox Pharmaceuticals commences Phase II clinical trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis

April 3, 2013

Aquinox Pharmaceuticals Completes US $18 Million Series C Financing

November 10, 2011

Aquinox Pharmaceuticals Initiates Two Phase IIa Clinical Studies in Airway Inflammation Following Successful Phase I

January 5, 2011

Aquinox Pharmaceuticals Receives Regulatory Clearance to Initiate First Clinical Study of AQX-1125, A Novel Oral Anti-Inflammatory Compound

September 15, 2010

Aquinox Pharmaceuticals appoints Csaba Szabó, M.D., Ph.D., Vice President, Research and Chief Scientific Officer

June 17, 2010

Aquinox Pharmaceuticals Completes US $25 Million Series B Financing

October 11, 2009

Aquinox Pharmaceuticals Selects AQX-1125 as Lead Clinical Candidate

July 10, 2008

Aquinox Pharmaceuticals Inc. Names Board Member

September 14, 2007

With help from Mother Nature: A Novel New Drug Discovery May Revolutionize Treatment of Inflammatory Diseases and Leukemia

June 12, 2007

Aquinox Pharmaceuticals Inc. Completes US$14.5 million Series A financing